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Objectives The aim of this study was to identify predictors of clinical events after XIENCE V (Abbott
Vascular, Santa Clara, California) stenting.
Background The XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System [EECSS] USA Post-
Approval) study is a prospective, multicenter, Food and Drug Administration-required post-approval
study to examine safety and effectiveness in real-world settings. After an initial 5,062 patients, 2,999
more were included as part of the DAPT (Dual Antiplatelet Therapy) trial (total n  8,061).
Methods One-year clinical events, including stent thrombosis (ST), cardiac death/myocardial infarc-
tion (MI), target lesion failure, and target lesion revascularization, were adjudicated according to
Academic Research Consortium criteria, with ST and cardiac death/MI as primary and co-primary
endpoints. Demographic, clinical, and procedural variables were assessed by multivariable analysis.
A time-dependent covariate assessed the association between DAPT usage and ST.
Results Roughly 61% were off-label; 85.6% remained on DAPT without interruption through 1 year.
Incidences of deﬁnite/probable ST, cardiac death/MI, target lesion failure, and target lesion revascu-
larization were 0.80% (95% conﬁdence interval [CI]: 0.61% to 1.03%), 7.1% (95% CI: 6.51% to 7.68%),
8.9% (95% CI: 8.30% to 9.60%), and 4.3% (95% CI: 3.82% to 4.75%), respectively. Several indepen-
dent clinical and angiographic predictors were identiﬁed for each outcome. Predictors of ST in-
cluded DAPT interruption 30 days (hazard ratio [HR]: 8.63, 95% CI: 2.69 to 27.73, p  0.0003), renal
insufﬁciency (HR: 3.72, 95% CI: 1.71 to 8.09, p  0.0009), and total stent length (HR: 1.30,
95% CI: 1.16 to 1.47, p  0.0001). A DAPT interruption 30 days was not predictive of ST.
Conclusions In this large, real-world population, XIENCE V demonstrated low event rates at 1 year,
with several independent predictors. Early DAPT interruption (30 days) was the most potent pre-
dictor of ST, whereas delayed interruption (30 days) was not predictive. (XIENCE V Everolimus
Eluting Coronary Stent System [EECSS] USA Post-Approval Study; NCT00676520) (J Am Coll Cardiol
Intv 2012;5:626–35) © 2012 by the American College of Cardiology Foundation
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627The rapid uptake of the initial first-generation drug-eluting
stents (DES) in cardiovascular practice was subsequently
tempered by a perception of increased incidence of late stent
thrombosis (ST), prompting declines in DES use (1–3).
arge meta-analyses of the pivotal randomized controlled
rials and several “real-world” registries were then evaluated
nd confirmed an increased incidence of very late ST (4–6).
ewer second-generation DES were targeted to maintain
or surpass) the antirestenotic efficacy of first-generation
ES while improving their long-term safety, particularly
ith regard to the incidence of ST. The XIENCE V
verolimus-eluting coronary stent system (EECSS) (Abbott
ascular, Santa Clara, California) has potential advantages
ver first-generation DES, including thinner struts, reduced and
iocompatible polymer layer, early yet complete drug elution, and
se of a novel sirolimus derivative (7). Its efficacy in reducing
n-stent restenosis and major adverse cardiac events (MACE)
ompared with the paclitaxel-eluting stent was confirmed in
ultiple randomized controlled trials (8–12). However, perfor-
ance in a large, complex “real-world” clinical setting, including
off-label” scenarios, remains uncertain, especially with regard to
ates of low-frequency safety events, such as ST (13).
Recently, there has been concern that trial results seen
utside the United States might not mirror those noted
ithin the United States, for reasons that remain unclear (14).
ccordingly, the current study is the largest multicenter pro-
pective evaluation of the XIENCE V EECSS in a complex
real-world” patient population within the United States.
ne-year major adverse clinical events including both early
nd late ST and their independent predictors are reported
nd discussed, with particular attention to the predictive
ower of clinical and angiographic factors, including pre-
ature interruption of dual antiplatelet therapy (DAPT).
ethods
Study design. The XIENCE V USA (IDE G050050)
tudy (XIENCE V Everolimus Eluting Coronary Stent
ystem [EECSS] USA Post-Approval) is a prospective,
pen-label, multicenter, observational, single-arm trial de-
igned to further inform the safety evaluation of the EECSS
uring commercial use in real-world settings. A total of
,061 patients who underwent EECSS implantation were
nrolled from 192 sites in the United States. The study had
enrollment phases. The first enrollment phase started
rom July 2008 to December 2008 with 5,062 patients. The
econd enrollment phase was initiated to support the Food
nd Drug Administration (FDA) DAPT initiative, which
tarted from August 2009 to February 2010 with 2,999
atients.
All patients who could provide written informed consent
nd were treated only with EECSS during the index
rocedure were eligible. There were no additional clinical
escriptors or angiographic exclusion criteria for either cnrollment phase. Stent implantation was performed ac-
ording to the standard practice of each site. Periprocedural
harmacotherapy was also determined by site-based clinical
ractice, and staged procedures were permitted. Antiplatelet
herapy for at least 1 year was recommended in patients who
re not at high risk of bleeding per guidelines, but antiplate-
et therapy was not otherwise mandated by protocol per se
15,16). There were no protocol required treatments or
ests, except that post-procedure cardiac enzyme collections
ere required during the second enrollment phase per FDA
equest.
All patients were clinically followed at 14 days, 30 days,
nd 6 months either by telephone contacts or office visits.
he 1-year visit was conducted in office. There was no
andatory angiographic follow-up in this study. Planned
ollow-up in patients from the
rst enrollment phase will con-
inue for 5 years from the index
rocedure and will be reported
nnually. Eligible patients who
ere enrolled during the second
nrollment phase were random-
zed to different DAPT arms at
year and will be followed up at
5, 24, 30, and 33 months ac-
ording to the DAPT study
17). The remaining patients
rom the second enrollment
hase will not be followed up
ny further.
The primary endpoint was the
ncidence of Academic Research
onsortium (ARC)-defined defi-
ite and probable ST. The co-
rimary endpoint was the com-
osite rate of cardiac death and
ny ARC-defined myocardial
nfarction (MI) at 1 year. Other
ajor prospectively identified
econdary endpoints included target lesion failure (TLF);
he composite rate of cardiac death, any MI attributed to the
arget vessel, and clinically indicated target lesion revascu-
arization (CI-TLR); major bleeding complications defined
y Thrombolysis in Myocardial Infarction grade; and clin-
cal device and procedural success. Clinical device success
as defined as achievement of a final in-stent residual
iameter stenosis of 50% assessed by online quantitative
oronary angiography or visual estimation, using XIENCE V,
nd without device malfunction. Clinical procedural success
as defined as achievement of a final in-stent diameter
tenosis 50% by online quantitative coronary angiography
r visual estimation—using XIENCE V, with or without
ny adjunctive devices—and without the occurrence of
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
CI  confidence interval
DAPT  dual antiplatelet
therapy
DES  drug-eluting stent(s)
EECSS  everolimus-eluting
coronary stent system
FDA  Food and Drug
Administration
HR  hazard ratio
MACE  major adverse
cardiac event(s)
MI  myocardial infarction
ST  stent thrombosis
TLF  target lesion failure
TLR  target lesion
revascularization
WHO  World Health
Organizationardiac death, target vessel MI (Q-wave and non–Q-wave
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628MI), or repeat revascularization of the target lesion during
the health care facility stay. “Off-label” was characterized as
patients with any of the following: baseline lesion length
28 mm; reference vessel diameter 2.5 or 4.25 mm;
chronic total occlusion; graft lesion; bifurcation with side
branch 2 mm; ostial; left main; restenosis; more than 2
lesions stented in the same vessel; more than 2 vessels
treated; acute MI; renal insufficiency; ejection fraction
30%; or staged procedure.
At the request of the FDA, ARC-defined MI was
prospectively adjudicated and reported in this study. For
purposes of comparisons with historical data, MI was also
adjudicated by World Health Organization (WHO) crite-
ria. Real-world usage of DAPT within the first year was also
examined in this study. All clinical endpoint events, includ-
ing ST, death, MI, revascularization, and major bleeding,
were adjudicated by an independent clinical events commit-
tee at the Cardiovascular Research Foundation (New York,
New York). The data and safety monitoring board (Axio,
Seattle, Washington) reviewed cumulative study safety data
on a regular basis to ensure public safety.
The study monitoring plan included up to 30% of
randomly selected patients with 100% source document
verification in the first enrollment phase, and 5% of ran-
domly selected patients in the second enrollment phase. All
site-reported adjudicable endpoint events were reviewed and
source-verified. In addition, sites with low rates of reported
events received additional training and monitoring visits to
confirm rigorous event reporting. The study complied with
the Declaration of Helsinki for investigation in human
beings and was approved by the institutional review board at
each study center. The XIENCE V USA study is registered
with ClinicalTrials.gov (NCT00676520).
Statistical analysis. All analyses were performed on pre-
pecified analytical populations on the basis of available
ata. Patient/angiographic characteristics and event rates
ere analyzed with descriptive statistics with SAS (version
.1 or higher; SAS Institute, Cary, North Carolina). The 2
nrollment phases had similar designs, eligibility criteria,
ndpoint definitions, and adjudication processes and there-
ore were pooled together. Binary or categorical variables
ere presented as percentages. Means and standard devia-
ions were presented for continuous variables. The time-to-
vent curves were displayed by Kaplan-Meier methods.
The DAPT medication usage data were collected on the
asis of patient reported history. Interruption of DAPT was
efined as cessation of either aspirin or thienopyridine
herapy for at least 1 day within the time window, including
hose who discontinued and did not resume dual therapy.
To identify predictors of ST, cardiac death, ARC-defined
I, TLF, and target lesion revascularization (TLR), a total
f 36 variables—including 16 clinical variables, 12 angio-
raphic variables, and 8 procedural variables—were assessed
or each of the aforementioned endpoints with multivari-ble, stepwise, Cox regression analysis with predictor vari-
bles entered into the model at the 0.05 significance level. In
ddition, a time-dependent covariate was used to capture
he DAPT interruption pattern to assess any association
ith subsequent ST occurrence.
esults
Baseline characteristics of study patients. Eight thousand
ixty-one patients were prospectively enrolled, and 11,168
esions were treated, including 61% for “off-label” indica-
ions. Clinical device success was 99.8%, and clinical pro-
edural success was 97.3%. Clinical, angiographic, and
rocedure-specific characteristics are noted in Tables 1 and 2.
verage age was 65 years, roughly 70% were male, and
early 36% were diabetic. Twenty-nine percent of patients
resented with unstable angina, and 14.8% presented with
cute MI. Restenosis, bifurcation, and ostial disease were
ach represented in roughly 10% of lesions, and average
tent length approached 30 mm/patient (1.6 stents/patient).
pproximately 94.2% of patients continued to receive
APT without any interruption through 30 days, and
5.6% continued to receive DAPT without any interruption
hrough 1 year (Table 3). Approximately 89% of the overall
opulation has completed 1-year follow-up.
Primary, co-primary, and other endpoints. One-year major
dverse clinical events are presented in Table 4. The ARC
riteria are used for definite/probable ST, whereas both
RC and WHO criteria are presented for MI. Figure 1
epicts time-to-event curves for cardiac death/MI, TLF,
T, and TLR, according to both ARC and WHO criteria.
T occurred in 0.8% at 1 year and was roughly evenly split
Table 1. Patient Demographic Data and Risk Factors (N  8,061)
Age (yrs) 64.57 10.81
Male 5,612 (69.6%)
All diabetes mellitus 2,860 (35.8%)
Dyslipidemia requiring medication 6,501 (82.9%)
Hypertension requiring medication 6,701 (83.9%)
Current tobacco user 1,707 (22.3%)
Renal insufﬁciency 841 (10.5%)
Anemia 567 (7.2%)
History of previous MI 2,218 (29.7%)
Stable angina 3,408 (44.6%)
Unstable angina 2,203 (28.9%)
AMI 1,058 (14.8%)
Multi-vessel disease 3,208 (39.8%)
LVEF 30% 203 (3.4%)
Past cardiac intervention* 3,986 (50.7%)
PCI 3,072 (39.1%)
CABG 1,292 (16.4%)
Values are mean SD or n (%). *Patient can be counted in more than 1 category.
AMI acute myocardial infarction; CABG coronary artery bypass graft surgery; LVEF leftventricular ejection fraction; PCI percutaneous coronary intervention.
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629between acute/early (30 days) and late (30 to 365 days)
time periods. Overall incidence of death was 2.3%, with
slightly over one-half being cardiac-related (1.3%). Myocar-
dial infarction occurred in 6.2% by ARC criteria and 2.1%
by WHO criteria, with cardiac death/MI rates 7.1% and
3.1%, respectively. The majority of MIs were non-Q-wave.
Target lesion failure and TLR rates were low, the latter
approximating 4% at 1 year.
Univariate and multivariable predictors. Several clinical,
rocedural, or lesion-specific univariate predictors of ST,
ardiac death/MI (ARC-criteria), TLF (ARC-criteria), and
LR were identified and are presented in Table 5. Strong
redictors (hazard ratio [HR]: 2.0) of ST in univariate
nalysis included DAPT interruption 30 days, ejection
raction 30%, renal insufficiency, lesion length 22 mm,
ulti-vessel intervention, in-stent restenosis, multi-stent
mplanted, type B2/C lesion, prior coronary artery bypass
Table 2. Lesion and Procedural Characteristics
Target vessel
RCA 3,673 (32.9%)
LAD 4,178 (37.4%)
LCX 2,624 (23.5%)
LMCA 182 (1.6%)
Graft 510 (4.6%)
ACC/AHA B2/C lesion 4,628 (49.9%)
Restenosis 980 (8.8%)
Lesion length (mm) 15.9 9.4
RVD (mm) 3.02 0.53
Pre-procedure DS (%) 84.0 10.9
TIMI 0 3 months old 214 (2.0%)
Bifurcation 1,085 (9.7%)
Ostial 1,177 (11.2%)
Lesions treated 1.4 0.7
Direct stenting 4,105 (36.8%)
Post-dilation done 6,235 (55.9%)
Stents/patient 1.6 0.9
Stents/lesion 1.2 0.4
Stent length/patient 29.2 19.1
Stent length/lesion 21.2 11.3
Values are n (%) or mean SD. N 8,061 patients; N 11,168 lesions.
ACC/AHAAmerican College of Cardiology/American Heart Association class; DS diameter
stenosis; LAD left anterior descending coronary artery; LCX left circumflex coronary artery;
LMCA leftmain coronary artery; RCA right coronary artery: RVD reference vessel diameter;
TIMI Thrombolysis in Myocardial Infarction grade.
Table 3. DAPT Usage
No Interrup
Through 30
Aspirin 95.9%
Thienopyridine 97.4%
DAPT (aspirin and thienopyridine) 94.2%
Values are % of patients. Dual antiplatelet therapy (DAPT) interruptiowindow.raft surgery, multi-vessel disease, and multi-lesion inter-
ention. Strong predictors (HR: 2.0) of cardiac death/MI
ncluded renal insufficiency, graft intervention, multi-vessel
ntervention, and bailout stent use, whereas graft interven-
ion, previous brachytherapy, and multi-vessel intervention
ere strong predictors of TLF. Target lesion revasculariza-
ion was strongly (HR: 2.0) predicted by in-stent reste-
osis, prior brachytherapy, left main intervention, graft
ntervention, prior coronary artery bypass graft surgery, prior
ercutaneous coronary intervention, multi-vessel interven-
ion, multi-lesion intervention, multi-vessel disease, and
ulti-stent implanted.
Multivariable predictors of all 4 outcomes are presented
n Table 6. There were only 3 independent predictors of ST,
he strongest being DAPT interruption within 30 days
HR: 8.63, 95% confidence interval [CI]: 2.69 to 27.73, p
.0003), followed by renal insufficiency (HR: 3.72, 95% CI:
.71 to 8.09, p  0.0009) and total length of stents (HR:
.30, 95% CI: 1.16 to 1.47, p  0.0001). Neither diabetes
No Interruption
Through 180 Days
No Interruption
Through 1 Yr
93.4% 91.4%
94.7% 90.2%
90.5% 85.6%
defined as medication not taken for at least 1 day through the time
Table 4. 1-Year Major Clinical Outcomes (N  8,061)
Death 175 (2.3%)
Cardiac death 99 (1.3%)
MI (ARC) 468 (6.2%)
Q-wave 38 (0.5%)
Non–Q-wave 435 (5.8%)
MI (WHO) 158 (2.1%)
Q-wave 38 (0.5%)
Non–Q-wave 122 (1.6%)
Cardiac death/MI (ARC) 534 (7.1%)
Cardiac death/MI (WHO) 237 (3.1%)
TLF (cardiac death/TVMI [ARC]/CI-TLR) 674 (8.9%)
TLF (cardiac death/TVMI [WHO]/CI-TLR) 479 (6.4%)
TLR 322 (4.3%)
TVR, non-TLR 166 (2.2%)
TIMI major bleeding 192 (2.6%)
ST (ARC deﬁnite/probable) 59 (0.80%)
Acute ST (0–24 h) 7 (0.09%)
Subacute ST (24 h to 30 days) 25 (0.31%)
Late ST (30 days to 365 days) 27 (0.37%)
Values are n (%).
ARC  Academic Research Consortium; CI  clinically indicated; MI  myocardial infarction;
ST stent thrombosis; TLF target lesion failure; TLR target lesion revascularization; TVMI
myocardial infarction attributed to target vessel; TVR  target vessel revascularization; WHO 
World Health Organization.tion
Days
n was
n here
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630nor later DAPT interruption (30 days) was a predictor of
ST. In-stent restenosis was the strongest predictor of TLR.
Of note, neither lesion length 22 mm nor bifurcation
disease predicted TLR, whereas total length of stents
Figure 1. Time-to-Event Curves
Time-to-event curves for: (A) cardiac death and Academic Research Consortium
Organization (WHO)-deﬁned MI; (C) target lesion failure (TLF) (the composite o
target lesion revascularization [TLR]); (D) TLF (the composite of cardiac death,
deﬁned deﬁnite and probable stent thrombosis (ST); (F) TLR. Event rates showindependently predicted ST, cardiac death/MI, and TLF.Diabetes, graft intervention, and multi-vessel disease inde-
pendently predicted TLF and TLR, whereas renal insuffi-
ciency was a predictor for ST, cardiac death/MI, and TLF;
and ostial disease predicted both TLF and TLR. Female sex
)-deﬁned myocardial infarction (MI); (B) cardiac death and World Health
iac death, ARC-deﬁned MI attributed to target vessel and clinically indicated
deﬁned MI attributed to target vessel and clinically indicated TLR); (E) ARC-
were calculated at 365 days with Kaplan-Meier methods.(ARC
f card
WHO-predicted cardiac death/MI and therefore also TLF,
to 4.
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631whereas use of small diameter stents (2.5 mm) only pre-
dicted TLR.
Discussion
The current study represents the largest, prospective single-
arm trial of EECSS in “real-world” clinical practice within
Table 5. Univariate Predictors of 1-Year Clinical Outc
Variables ST
Age 65 yrs NS
Female NS
Current smoker NS
Diabetes Rx NS
HyperteNAion Rx NS
Hypercholesterolemia Rx NS
Prior CABG 2.15 (1.09–4.23)
Prior PCI NS
CCS III/IV angina NS
Prior MI NS
Brachytherapy NS
AMI NS
Renal insufﬁciency 3.21 (1.66–6.22)
Stroke NS
LVEF 30% 4.67 (1.63–13.43)
Multi-vessel disease 2.17 (1.20–3.93)
LAD NS
Left main vessel NS
Graft NS
Heavy calciﬁcation NS
2.5-mm stent 1.98 (1.10–3.57)
Pre-procedure DS% 70% NS
Pre-procedure TIMI 0.70 (0.53–0.93)
Lesion length 22 mm 2.77 (1.50–5.12)
ISR 2.55 (1.13–5.77)
Bifurcation NS
Ostial NS
B2/C lesion 2.24 (1.07–4.66)
Pre-dilation NS
Post-dilation NS
Max balloon pressure 1.08 (1.02–1.15)
Treated lesions, n 2.08 (1.16–3.74)
Treated vessels, n 2.57 (1.31–5.05)
Bailout stent use NS
Stents implanted, n 2.45 (1.34–4.48)
Stent length (10 mm) 1.30 (1.18–1.43)
DAPT interruption* 30 days 7.32 (2.66–20.14)
DAPT interruption* 30 days NS
Values are hazard ratio (95% confidence interval) for variables that rea
those variables were not included in themodel. *The DAPT interruptio
within 1 year from procedure. The timing of interruption was based on
CD/MI cardiac death andmyocardial infarction (per ARC); DS dia
medication; ST stent thrombosis (ARCdefinite/probable); TLF targ
vessel and clinically indicated TLR); other abbreviations as in Tables 1the United States, extending the results of the originalXIENCE V USA study and allowing a more robust and
contemporary evaluation of both incidence and predictors of
outcome. Characteristic of current practice, one-third pre-
sented with unstable angina, roughly 15% presented with
acute MI, and a significant percentage of patients had
diabetes, renal insufficiency, and high-risk angiographic
findings. Approximately 94% continued to receive DAPT
/MI (ARC) TLF (ARC) TLR
(1.03–1.47) 1.20 (1.03–1.41) NS
(1.15–1.66) 1.31 (1.11–1.54) NS
NS NS 0.68 (0.49–0.93)
(1.24–1.78) 1.55 (1.32–1.82) 1.67 (1.33–2.10)
NS NS NS
NS NS NS
(1.24–1.90) 1.76 (1.46–2.11) 2.28 (1.77–2.92)
NS 1.34 (1.14–1.57) 2.21 (1.75–2.80)
NS NS NS
(1.18–1.74) 1.36 (1.14–1.61) NS
NS 2.19 (1.04–4.61) 3.30 (1.36–8.00)
(1.01–1.65) NS NS
(1.73–2.70) 1.87 (1.52–2.31) 1.55 (1.13–2.14)
(1.03–2.16) NS NS
(1.15–2.77) 1.60 (1.06–2.42) NS
(1.37–1.96) 1.81 (1.55–2.12) 2.05 (1.63–2.57)
NS 0.84 (0.72–0.99) 0.78 (0.62–0.99)
(1.17–2.86) 1.80 (1.20–2.68) 2.62 (1.60–4.27)
(1.55–2.79) 2.24 (1.74–2.89) 2.55 (1.81–3.60)
NS NS NS
NS 1.31 (1.11–1.53) 1.55 (1.24–1.95)
NS NS NS
NS NS NS
(1.38–2.04) 1.57 (1.32–1.87) NS
NS 1.71 (1.35–2.18) 3.38 (2.55–4.49)
NS NS NS
(1.12–1.78) 1.62 (1.33–1.97) 1.83 (1.39–2.41)
(1.24–1.86) 1.57 (1.31–1.87) 1.56 (1.20–2.03)
NS NS NS
NS NS NS
(1.02–1.07) 1.05 (1.03–1.07) 1.05 (1.02–1.09)
(1.37–1.97) 1.85 (1.58–2.17) 2.10 (1.67–2.63)
(1.61–2.50) 2.03 (1.67–2.46) 2.15 (1.63–2.84)
(1.24–3.25) 1.86 (1.19–2.91) NS
(1.44–2.06) 1.87 (1.59–2.18) 2.01 (1.60–2.53)
(1.12–1.21) 1.16 (1.13–1.20) 1.15 (1.09–1.20)
NS NS NS
NS NS NS
atistical significance (p 0.05). NA indicates not applicable, because
efined as cessation of either aspirin or thienopyridine for at least 1 day
the first interruption occurred for that patient.
tenosis; ISR in-stent restenosis; NS not significant; Rx requiring
failure (a compositeof cardiacdeath,MI [perARC] attributed to targetomes
CD
1.23
1.38
1.49
1.53
1.43
1.29
2.16
1.49
1.78
1.64
1.83
2.08
1.68
1.41
1.52
1.05
1.64
2.01
2.00
1.72
1.16
ched st
nwas d
when
meter s
et lesionwithout any interruption within 30 days, and 85% continued
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632to receive DAPT without any interruption within 1 year.
Despite this complex patient population, very low rates of
all major adverse clinical events were noted, including 0.80%
ST and roughly 4% TLR rates. Several independent pre-
dictors were identified in multivariable analysis. Impor-
tantly, only 3 characteristics seem to independently predict
ST, with clinical predictors dominating. Of these, early
(30 days) interruption of DAPT conferred an almost
9-fold increased risk, whereas interruption after 30 days did
not seem to elevate risk, reinforcing the importance of
exploring shorter durations of DAPT in patients treated
with EECSS.
The safety and efficacy of the EECSS has been confirmed
in several completed and relatively large randomized con-
trolled trials, including the SPIRIT IV trial (SPIRIT IV
Clinical Trial: Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in the Treat-
ment of Subjects With de Novo Native Coronary Artery
Lesions) within the United States and both the COMPARE
Table 6. Multivariate Predictors of 1-Year Clinical Ou
Multivariate
ARC deﬁnite/probable ST DAPT interrupti
Renal insufﬁcien
Total length of
Cardiac death and ARC MI (CD/MI) Renal insufﬁcien
Female
Prior MI
Multi-vessel inte
Diabetes Rx
Total length of
TLF Bailout stent us
Target vessel: g
ISR
Diabetes Rx
Renal insufﬁcien
Multi-vessel dise
Female
Prior CABG
Ostial lesion
Total length of
TLR ISR
Prior PCI
Prior CABG
Diabetes Rx
Target vessel: g
Multi-vessel dise
Multiple lesions
Ostial lesion
2.5-mm stent
*The DAPT interruption was defined as cessation of either aspirin or t
interruption was based on when the first interruption occurred for tha
Abbreviations as in Tables 1 to 5.(A Randomized Controlled Trial of Everolimus-elutingStents and Paclitaxel-eluting Stents for Coronary Revascu-
larization in Daily Practice: The COMPARE Trial) and
RESOLUTE All-Comers (RESOLUTE-III All-comers
Trial: A Randomized Comparison of a Zotarolimus-
Eluting Stent With an Everolimus-Eluting Stent for Per-
cutaneous Coronary Intervention) trials outside the United
States (18–20). Yet, such evaluations might be limited by
relatively strict entry criteria, the selection bias inherent to
all randomized controlled trials, and relatively low patient
enrollment that might not fully characterize rare events,
such as ST. As a result, baseline characteristics of these
pivotal randomized controlled trials tended to include pa-
tients of lower risk than the XIENCE V USA trial.
Compared with the SPIRIT IV trial, for example, the
XIENCE V USA trial included a numerically higher
percentage with diabetes, unstable angina, and previous MI
as well as a higher mean reference vessel diameter (reflecting
the lack of strict inclusion or exclusion criteria). Dual
antiplatelet therapy was used approximately 95% at 1 year in
es
ctors Hazard Ratio (95% CI) p Value
0 days 8.63 (2.69–27.73) 0.0003
3.72 (1.71–8.09) 0.0009
(10 mm) 1.30 (1.16–1.47) 0.0001
1.64 (1.22–2.19) 0.0010
1.46 (1.18–1.82) 0.0006
1.43 (1.15–1.78) 0.0014
on 1.40 (1.05–1.85) 0.0214
1.34 (1.07–1.67) 0.0096
(10 mm) 1.16 (1.10–1.22) 0.0001
1.88 (1.15–3.07) 0.0188
1.78 (1.28–2.47) 0.0007
1.47 (1.12–1.92) 0.0048
1.46 (1.22–1.76) 0.0001
1.46 (1.14–1.86) 0.0026
1.41 (1.16–1.70) 0.0004
1.41 (1.17–1.69) 0.0003
1.35 (1.06–1.71) 0.0156
1.26 (1.01–1.58) 0.0398
(10 mm) 1.14 (1.10–1.19) 0.0001
2.28 (1.63–3.19) 0.0001
1.69 (1.27–2.25) 0.0003
1.67 (1.22–2.29) 0.0014
1.60 (1.23–2.07) 0.0004
1.60 (1.04–2.47) 0.0309
1.52 (1.13–2.03) 0.0054
d 1.50 (1.12–2.01) 0.0070
1.39 (1.03–1.89) 0.0328
1.36 (1.04–1.77) 0.0241
yridine for at least 1 day within 1 year from procedure. The timing of
t.tcom
Predi
on* 3
cy
stents
cy
rventi
stents
age
raft
cy
ase
stents
raft
ase
treate
hienop
t patienthe SPIRIT IV trial, compared with 85% in the XIENCE V
a
m
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633USA trial, whereas usage at 1 year in the Dutch single-
center COMPARE trial was 70%. Despite these differ-
ences, the per-WHO incidences of cardiac death/MI, TLF,
and TLR remained low albeit numerically higher in the
XIENCE V USA trial (3.1%, 6.4%, and 4.3%, respectively)
compared with the EECSS arm of the SPIRIT IV trial
(2.8%, 4.2%, and 2.5%, respectively), and rates of cardiac
death/MI and TLR were similar to the EECSS arm of the
COMPARE trial (4% and 2%, respectively). The EECSS
arm of the RESOLUTE All-Comers trial is perhaps more
comparable to the present study, with roughly 65% “off-
label” use compared with the 61% “off-label” use of the
XIENCE V USA trial (20). Rates of TLF (6.4% vs. 8.3%)
and cardiac death/MI (3.1% vs. 5.4%) are numerically lower
in the XIENCE V USA trial, with similar rates of TLR
(4.3% vs. 3.4%).
These 1-year results are similar to other “real-world”
registries of DES, including a 12-month MACE rate of
7.5% (cardiac death/MI 3.0%, TLR 4.5%) in the E-FIVE
(World-Wide Registry With The Endeavor Zotarolimus
Eluting Coronary Stent) Registry of the zotarolimus-eluting
stent (21). In addition, a 12-month MACE rate of 5.8%
was noted in the e-Cypher Registry of the sirolimus-eluting
stent, and 9-month MACE rates of 8.0% and 7.5% were
found for the sirolimus-eluting and paclitaxel-eluting stents,
respectively, in the STENT (Strategic Transcatheter Eval-
uation of New Therapies) Registry, with again similar rates
in the REWARDS (Registry Experience at the Washing-
ton Hospital Center with Drug-Eluting Stents) Registry
(22–25). On the basis of these data, the EECSS seems to
perform as well or better at the 1-year mark than any other
available DES.
From an ST standpoint, studies of the EECSS to date
have indicated a very low 1% rate of ARC-defined
definite/probable ST at 1 year, regardless of baseline patient
population risk profile (18–20). However, there remains
concern that larger patient populations in complex “real-
world” patient subsets are required to accurately inform the
absolute rate of these low-frequency events in day-to-day
practice (13,17). Although the FDA-mandated DAPT
Trial—which recently completed enrollment—has included
over 20,000 patients, the allowance of all available DES as
well as bare-metal stents will ultimately limit its ability to
reflect the current incidence of ST for any individual stent.
Therefore results from the XIENCE V USA study provide
the most robust and practical estimate of ST in routine
practice. In this regard, the 0.80% rate of ST through 1 year
seen here (and consistent with the 0.7% rate in the EECSS
arms of both the COMPARE and RESOLUTE All-
Comers trials) is reassuring (19,20). Moreover, this rate is
numerically lower than that seen at 1 year with either the
first-generation or second-generation zotarolimus-eluting
stents (1.1% and 1.6%, respectively) (20,21). rThere are limited data on independent predictors of
major adverse clinical events with routine use of the EECSS.
Pooling data from several randomized controlled trials in
almost 7,000 patients comparing the EECSS with the
paclitaxel-eluting stent found that insulin-requiring diabe-
tes, hypertension, multi-lesion intervention, prior percuta-
neous coronary intervention, pre-procedure reference vessel
diameter, and LAD location all predicted MACE, with use
of the EECSS strongly protective (36% relative risk reduc-
tion) (26). However, whether all these factors would remain
predictive if the study were limited to the EECSS is unclear.
We found that both clinical and angiographic characteristics
continue to predict MACE when using a sole-EECSS
strategy. Not surprisingly, clinical characteristics such as
renal insufficiency, female sex, prior MI, and diabetes
dominated as predictors of cardiac death/MI, whereas
angiographic features such as in-stent restenosis, graft
intervention, multi-vessel disease, multi-lesion intervention,
ostial location, and 2.5-mm stent diameter dominated as
predictors of TLR. Target lesion failure, being a combina-
tion of cardiac death, target vessel MI, and clinically
indicated TLR, showed significant confluence of these
clinical and angiographic predictors.
The issue of ST has dominated the interventional cardi-
ology landscape for the past 5 years, with newer-generation
stents developed with dual goals of both reducing rates of
ST at all time points and perhaps providing sufficient safety
data to allow earlier discontinuation or interruption of
DAPT. In the current study, not only were ST rates low but
only 3 independent predictors of ST were noted when using
EECSS. Two clinical criteria, namely renal insufficiency
and early (30 days) interruption of DAPT, emerged as the
only clinical predictors, whereas total stent length emerged
as the sole angiographic predictor (and a relatively weak one
by comparison). Although these have been noted before, the
fact that only 3 predictors remain with use of this particular
DES, with clinical variables by far dominating, is indeed
notable, as is the absence of several previously identified
predictors, such as diabetes, reduced ejection fraction, and
bifurcation disease (27). Additionally, the current study is
the first to suggest that DAPT interruption after 30 days
does not increase the incidence of ST within the first
post-procedure year when using the EECSS. Although the
current study cannot be used to advocate for interruption of
DAPT before 1 year (or, if necessary, after 30 days), it
might help confirm recent studies of 6-month DAPT, such
as the PRODIGY study (PROlonging Dual-antiplatelet
treatment after Grading stent-induced Intimal hyperplasia
study), and serve as the basis for further studies of extremely
short duration DAPT (28).
Study limitations. The main limitations of the current study
re its observational, nonrandomized nature, the lack of
andatory angiographic follow-up, and that there is cur-ently only 1-year follow-up. Comparisons between differ-
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634ent DES platforms cannot be drawn from the present study
and are included herein as hypothesis-generating only.
Importantly, because the concern with first-generation DES
is primarily related to very late (1 year) ST, the present
paper cannot address this issue. Furthermore, DAPT ad-
herence was assessed on the basis of patient reported history
rather than pill counts, and there were a relatively small
number of ST events and a large number of predictor
variables built into the model. For these reasons, the
interpretation of predictors, such as DAPT usage and their
relationship with ST, needs to be cautious. However, several
mechanisms were incorporated into the prospective
XIENCE V USA single-arm trial to improve generalizabil-
ity. Chief among these are the incorporation of few exclu-
sion criteria, namely inability to give informed consent and
use of stents other than the EECSS, rigorous data moni-
toring and high follow-up rates, independent endpoint
adjudication, and other quality-control methods that mirror
those found in high-quality randomized controlled trials. In
addition, prospectively defined analysis plans, random au-
diting of source documents in a large percentage of patients,
and descriptor and endpoint definitions identical to similar
randomized controlled studies were used. Thus, the large
patient database in the XIENCE V USA trial provided an
accurate evaluation of the actual incidence of major adverse
clinical events (including rare events, such as ST) and the
identification of multivariable predictors in contemporary,
real-world clinical practice with this second-generation
DES.
Conclusions
Incidences of all major adverse clinical events are low in the
first year after EECSS deployment in a large “real-world”
and complex patient population within the United States,
despite a low 85% use of DAPT through 1 year, and are
predicted generally by clinical and angiographic character-
istics, including diabetes, renal insufficiency, multi-vessel
disease, graft intervention, ostial disease, and total length of
stents. Only 3 characteristics (2 clinical and 1 angiographic)
predicted definite/probable ST within the first year, with
clinical predictors dominating. Premature interruption of
DAPT strongly predicted ST but only when stopped within
30 days of the procedure.
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